WO2018214914A1 - 微米鱼油组合物及其制备方法与用途 - Google Patents

微米鱼油组合物及其制备方法与用途 Download PDF

Info

Publication number
WO2018214914A1
WO2018214914A1 PCT/CN2018/088044 CN2018088044W WO2018214914A1 WO 2018214914 A1 WO2018214914 A1 WO 2018214914A1 CN 2018088044 W CN2018088044 W CN 2018088044W WO 2018214914 A1 WO2018214914 A1 WO 2018214914A1
Authority
WO
WIPO (PCT)
Prior art keywords
fish oil
oil composition
micron
bar
present
Prior art date
Application number
PCT/CN2018/088044
Other languages
English (en)
French (fr)
Inventor
林咏翔
高振壹
Original Assignee
大江生医股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大江生医股份有限公司 filed Critical 大江生医股份有限公司
Priority to CN201880026492.8A priority Critical patent/CN110536607A/zh
Priority to US16/611,663 priority patent/US20200147147A1/en
Publication of WO2018214914A1 publication Critical patent/WO2018214914A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Definitions

  • the present invention relates to a micron fish oil composition and a process for the preparation thereof, and more particularly to the use of a micron fish oil composition for the preparation of a food product which enhances the bioabsorbability and bioavailability of an individual.
  • Fish oil is a fat that is taken from fat-rich fish, such as salmon, mackerel, squid or sardines. It is an oil-rich fish. Fish oil contains omega-3 fatty acids, mainly unsaturated fatty acids of eicosa pentanoic acid (EPA) and docosa hexaenoic acid (DHA). It is an important fatty acid that makes up phospholipids and cholesterol esters. It has many effects, such as lowering high cholesterol, lowering the risk of breast cancer, improving Alzheimer's disease and Parkinson's disease, and even having Helps to improve mental illnesses such as anxiety and anxiety.
  • omega-3 fatty acids mainly unsaturated fatty acids of eicosa pentanoic acid (EPA) and docosa hexaenoic acid (DHA). It is an important fatty acid that makes up phospholipids and cholesterol esters. It has many effects, such as lowering high cholesterol, lowering the risk of breast cancer, improving Alzheimer's disease and Parkinson's disease, and
  • it is an object of the present invention to provide a process for preparing a micron fish oil composition comprising the steps of: (a) mixing a composite plant colloid with fish oil and emulsification to obtain an emulsion; and emulsifying The material is homogenized under a pressure of 300 to 350 bar to obtain a micron fish oil composition.
  • Another object of the present invention is to provide a micron fish oil composition which is obtained by a method comprising the steps of: (a) mixing a composite plant colloid with fish oil and performing an emulsification treatment to obtain an emulsion; and (b) The emulsion is homogenized at a pressure of from 300 bar to 350 bar to obtain a micron fish oil composition.
  • Another object of the present invention is to provide a use of a micron fish oil composition as described above for the preparation of a food product which enhances the bioabsorbability and bioavailability of an individual.
  • the composite plant colloid is selected from the group consisting of Arabic gum, Guar gum, Xanthan, and any combination thereof.
  • the content of the composite vegetable colloid ranges from 6% by weight to 10% by weight, and the content of the fish oil ranges from 3% by weight to 15% by weight.
  • the content of gum arabic is 5.6% by weight to 8.4% by weight; the content of xanthan gum is 0.16% by weight to 0.24% by weight; the content of guar gum is 0.064% by weight to 0.096% by weight; and the content of fish oil is 7.2. Weight% to 10.8% by weight.
  • the micron fish oil composition has an average particle size between 180 nm and 250 nm.
  • the duration of the emulsification treatment is between 25 and 45 minutes. Preferably, the duration of the emulsification treatment is 35 minutes.
  • the emulsification treatment is carried out at 15 ° C to 30 ° C.
  • the emulsification treatment is carried out at 25 °C.
  • the homogenization treatment is carried out at 15 °C to 40 °C.
  • the homogenization treatment is carried out at 25 ° C to 30 ° C.
  • the micron fish oil composition of the present invention has the advantages of good emulsion stability compared with other branded emulsified fish oils, and is not easy to cause oil-water separation; and can improve the bioabsorbability and bioavailability of an individual. Usability; and the average particle size is lower than the average particle size of known fish oil products, thereby increasing the absorption rate and utilization rate of EPA and DHA.
  • Figure 1 is a chromatogram of the micron fish oil composition of the present invention (i.e., experimental group).
  • Figure 2 is a chromatogram of a fish oil product (i.e., comparative group) purchased from Melaleuca Co., Ltd.
  • Figure 3 is a photograph showing the appearance of the micron fish oil composition of the present invention by emulsification treatment.
  • Figure 4 is a photograph of the appearance of a fish oil product purchased from Melaleuca Co., Ltd. by emulsification treatment.
  • Fig. 5 shows the results of TSI measurement of the emulsified treatment of the micron fish oil composition of the present invention (i.e., the experimental group) and the fish oil product (i.e., the comparative group) purchased from Melaleuca Co., Ltd.
  • Figure 6 shows the results of particle size analysis of the micron fish oil composition of the present invention after homogenization treatment (i.e., experimental group).
  • Figure 7 shows the results of particle size analysis of the fish oil composition without homogenization (i.e., control group).
  • Figure 8 shows the results of particle size distribution of the micron fish oil composition of the present invention after homogenization treatment (i.e., experimental group).
  • Figure 9 shows the results of particle size distribution of the fish oil composition without homogenization (i.e., control group).
  • Figure 10 shows the subjects in the plasma after administration of the high pressure (300 bar to 350 bar) homogenized micron fish oil composition (i.e., experimental group) or the fish oil composition (i.e., control group) which has not been subjected to high pressure homogenization treatment of the present invention.
  • Figure 11 shows the subject in the plasma after administration of the high pressure (300 bar to 350 bar) homogenized micron fish oil composition (i.e., experimental group) or the fish oil composition (ie, control group) which has not been subjected to high pressure homogenization treatment of the present invention.
  • the concentration of DHA varied, where "#" indicates p ⁇ 0.1 and "*" indicates p ⁇ 0.05.
  • Figure 12 shows the subject in a red blood cell after administration of a high pressure (300 bar to 350 bar) homogenized micron fish oil composition (i.e., experimental group) or a fish oil composition (ie, a control group) which has not been subjected to high pressure homogenization treatment of the present invention.
  • concentration change of EPA where "#" indicates p ⁇ 0.1, and "*" indicates p ⁇ 0.05.
  • Figure 13 shows the subject in a red blood cell after administration of a high pressure (300 bar to 350 bar) homogenized micron fish oil composition (i.e., experimental group) or a fish oil composition (ie, a control group) which has not been subjected to high pressure homogenization treatment of the present invention.
  • concentration of DHA varied, where "#" indicates p ⁇ 0.1 and "*" indicates p ⁇ 0.05.
  • Figure 14 shows the subject in the plasma after administration of the high pressure (300 bar to 350 bar) homogenized micron fish oil composition (i.e., experimental group) or the fish oil composition (i.e., control group) which has not been subjected to high pressure homogenization treatment of the present invention.
  • Figure 15 shows the subject in a red blood cell after administration of a high pressure (300 bar to 350 bar) homogenized micron fish oil composition (i.e., experimental group) or a fish oil composition (ie, a control group) which has not been subjected to high pressure homogenization treatment of the present invention.
  • the food product according to the present invention can be prepared as a dispersible powder or a granule, a solution, a suspension, an emulsion, and the like.
  • the types of food products include, but are not limited to, health foods and nutritional supplements.
  • bioabsorbability means the ability to be taken up by an organism and digested for absorption and decomposition.
  • bioavailability means that the active ingredient or active moiety in a food product is absorbed and becomes a rate and amount that can be utilized systemically.
  • the composite plant colloid including gum arabic, xanthan gum and guar gum, wherein the content of gum arabic is 7% by weight, the content of xanthan gum is 0.2% by weight, guar gum
  • the content is 0.08% by weight, boiled in boiling water, and then mixed and stirred at 3,000 rpm for 2 hours to obtain a composite vegetable colloid mother liquor.
  • the mother liquor of the composite plant colloid is cooled to room temperature (25 ° C), and 10% by weight to 15% by weight is added.
  • Glycerin and 3% by weight to 15% by weight of fish oil (preferably 9% by weight) followed by mixing and stirring at 3,000 rpm for emulsification treatment for 25 minutes to 45 minutes to obtain an emulsion.
  • the emulsion is Homogenization is carried out at a pressure of from 300 bar to 350 bar to obtain the micron fish oil composition of the present invention.
  • FIG. 1 is a chromatogram of the micron fish oil composition of the present invention (ie, an experimental group);
  • FIG. 2 is a chromatogram of a fish oil product (ie, a comparative group) purchased from Melaleuca Co., Ltd.;
  • TSI values stabilized kinetic parameters
  • the TSI value reflects the stability of the emulsified sample. The higher the TSI value, the higher the stability variation, and the more unstable the dispersion of the emulsified sample.
  • Fig. 5 shows the results of TSI measurement of the emulsified treatment of the micron fish oil composition of the present invention (i.e., the experimental group) and the fish oil product (i.e., the comparative group) purchased from Melaleuca Co., Ltd. It can be seen from Fig.
  • the micro fish oil composition was homogenized using a high pressure homogenizer (GEA Niro Soavi) at a pressure of 300 bar to 350 bar as an experimental group.
  • a fish oil composition which was not subjected to homogenization treatment was used as a control group.
  • Taiwan Dachang Huajia Co., Ltd. to test the particle size of the experimental group and the control group, and use the NanoSight NS300 analyzer for detection.
  • the NS300 analyzer can quickly and automatically optimize the particle size distribution and concentration of all types of nanoparticles from 10 nm to 2000 nm in diameter. analysis. The results of this experiment are shown in Figures 6 to 9.
  • Figure 6 shows the results of particle size analysis of the micron fish oil composition of the present invention after homogenization treatment (i.e., the experimental group);
  • Figure 7 shows the results of particle size analysis of the fish oil composition without homogenization (i.e., the control group);
  • Fig. 9 shows the results of particle size distribution of the fish oil composition without homogenization treatment (i.e., control group).
  • the particle size of the experimental group was mainly concentrated at 100 nm to 400 nm, preferably between 180 nm and 250 nm, and the average particle diameter was 216.5 nm.
  • the particle size of the control group was mainly concentrated at 100 nm to 700 nm, and the average particle diameter was 382.8 nm.
  • the experimental results show that the high pressure homogenization treatment is the key to reduce the average particle size of the micro-emulsified fish oil of the present invention, and the average particle diameter of the micro-emulsified fish oil can be reduced from 382.8 nm to 216.5 nm, which significantly reduces the fish oil particle size. Therefore, the micron fish oil composition of the present invention has better bioabsorbability and bioavailability.
  • This experiment took the form of a crossover study and a placebo-controlled study.
  • a total of 4 healthy subjects were recruited to ingest 4.2 g of the high-pressure (300 bar to 350 bar) homogenized micron fish oil composition of the present invention (ie, experimental group) and fish oil composition without high pressure homogenization treatment (ie, control). group).
  • the concentration of EPA and/or DHA in the plasma and red blood cells of each subject was changed, thereby evaluating the organisms of the fish oil composition of the experimental group and the control group.
  • Absorption rate and utilization rate Subjects were given a low-fat diet during the trial and avoided eating foods such as fish, flaxseed, spirulina, blackcurrant oil and nuts that would cause experimental errors. The results of this experiment are shown in Figures 10 to 15.
  • Figure 10 shows the subjects in the plasma after administration of the high pressure (300 bar to 350 bar) homogenized micron fish oil composition (i.e., experimental group) or the fish oil composition (i.e., control group) which has not been subjected to high pressure homogenization treatment of the present invention.
  • Changes in concentration of EPA shows the subject's micron fish oil composition (ie, experimental group) or high pressure homogenized fish oil composition (ie, control group) treated with high pressure (300 bar to 350 bar) of the present invention.
  • FIG. 12 shows the fish oil combination of the micron fish oil composition (ie, the experimental group) or the high-pressure homogenized treatment of the subject treated with the high pressure (300 bar to 350 bar) of the present invention.
  • FIG. 13 shows that the subject was subjected to the high pressure (300 bar to 350 bar) homogenized micron fish oil composition (ie, experimental group) of the present invention or without high pressure.
  • FIG. 14 shows that the subject is subjected to the high pressure (300 bar to 350 bar) homogenized micron fish oil composition (ie, experimental group) of the present invention.
  • fish oil combination without high pressure homogenization The concentration of EPA and DHA in plasma after the control group (ie, the control group), that is, the sum of the changes in plasma EPA and DHA concentrations in each hour of FIG. 10 and FIG. 11; and FIG. 15 shows that the subject was subjected to the high pressure (300 bar) of the present invention.
  • the concentration of EPA and DHA in the red blood cells after the homogenized micron fish oil composition (ie, the experimental group) or the fish oil composition without the high pressure homogenization (ie, the control group) to 350 bar, ie, FIG. 12 and FIG. 13 The sum of changes in EPA and DHA concentrations in red blood cells at each hour.
  • the plasma EPA concentration measured by the experimental group was higher than that of the control group within 24 hours after taking the fish oil composition; as shown in Fig. 11, the experimental group was measured within 24 hours after taking the fish oil composition.
  • the concentration of DHA in the plasma was higher than that in the control group; as shown in Fig. 12, within 24 hours after taking the fish oil composition, the EPA concentration in the red blood cells measured by the experimental group was higher than that of the control group; Within 24 hours after the fish oil composition, except for the 4th hour, the DHA concentration in the red blood cells measured by the experimental group was higher than that of the control group; as shown in Fig. 14, within 24 hours after the fish oil composition was taken, the experimental group was measured.
  • the concentration of EPA and DHA in the plasma was higher than that in the control group. Especially at the 6th hour, the concentration of EPA and DHA in the plasma measured by the experimental group was 5.5 times that of the control group. As shown in Fig. 15, the fish oil composition was taken. Within the next 24 hours, the concentration of EPA and DHA in the red blood cells measured by the experimental group was higher than that of the control group. Especially at the 8th hour, the concentration of EPA and DHA in the red blood cells measured by the experimental group was 7.4 times that of the control group.
  • the experimental results of this example show that the micron fish oil composition of the present invention can effectively enhance the bioabsorbability and bioavailability of an individual (e.g., a human body).
  • the foregoing experimental results show that the inoculating the micron fish oil composition of the present invention after high pressure homogenization is higher than the high oil homogenized fish oil composition in 24 hours regardless of the concentration of EPA and DHA in plasma or red blood cells.
  • the micron fish oil composition after high pressure homogenization can increase the EPA and DHA content in plasma by 5.5 times, and increase the EPA and DHA content of red blood cells by 7.4 times, which can confirm that the micro-emulsified fish oil composition of the present invention can be significantly improved. Absorption rate and utilization rate of fish oil for human body.
  • micron fish oil composition of the present invention has been confirmed by experiments to have at least the following effects: stable emulsification condition, excellent dispersion stability, small average particle diameter, and effective promotion of bioabsorbability and bioavailability of an individual. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
  • Fats And Perfumes (AREA)

Abstract

一种微米鱼油组合物及其制备方法，所述制备方法包括将复合植物胶体与鱼油混合并进行乳化处理得到乳化物，将该乳化物在300bar至350bar的压力下进行均质处理得到。所述微米鱼油组合物可用于制备增进个体的生物吸收性及生物可利用性的食品。

Description

微米鱼油组合物及其制备方法与用途
相关申请的交叉引用
本申请主张在2017年5月23日在美国提交的美国专利申请号No.62/510,214的优先权，其全部内容通过引用包含于此。
技术领域
本发明是有关于一种微米鱼油组合物及其制备方法，尤其是微米鱼油组合物在制备增进个体的生物吸收性(bioabsorbability)及生物可利用性(bioavailability)的食品产品中的用途。
背景技术
鱼油(fish oil)是从富含脂肪的鱼类体内取出的油脂，像是鲑鱼、青花鱼、鲱鱼或沙丁鱼等，都属于富含油质的鱼。鱼油含ω-3脂肪酸(omega-3 fatty acids)，主要是二十碳五烯酸(eicosa pentanoic acid，EPA)与二十二碳六烯酸(docosa hexaenoic acid，DHA)的不饱和脂肪酸，它是组成磷脂、胆固醇酯的重要脂肪酸，其具有许多功效，如降低高胆固醇、降低乳癌风险、改善阿兹海莫症(Alzheimer′s disease)及帕金森斯症(Parkinson′s disease)、甚至有助于改善忧虑症及焦虑症等心理疾病。
为了补充EPA及DHA，许多人会直接服用含有鱼油的食品产品。目前市面上含有鱼油的食品产品大多为胶囊的形式，而补充鱼油的人群多为老人与儿童，呈胶囊形式的食品产品容易发生不易吞食并增加噎到的风险。另外，一般含有鱼油的食品产品对于人体的吸收性及可利用性并不佳，并未考虑到ω-3脂肪酸的吸收率，造成服用进入人体的EPA及DHA浓度不符保健需求。因此，若能开发出可增进个体的生物吸收性及生物可利用性的微米鱼油组合物，将为有此需求的使用者带来莫大福音并对本领域的技术带来进一步突破。
发明内容
有鉴于此，本发明的一个目的在于提供一种用于制备微米鱼油组合物的 方法，包含下列步骤：(a)将复合植物胶体与鱼油混合并进行乳化处理，以得到乳化物；以及将乳化物在300bar至350bar的压力下进行均质处理，得到微米鱼油组合物。
本发明的另一个目的在于提供一种微米鱼油组合物，通过包含下列步骤的方法而被制得：(a)将复合植物胶体与鱼油混合并进行乳化处理，以得到乳化物；以及(b)将乳化物在300bar至350bar的压力下进行均质处理，以得到微米鱼油组合物。
本发明的另一目的在于提供一种如前所述的微米鱼油组合物在制备增进个体的生物吸收性及生物可利用性的食品产品中的用途。
在本发明的一个实施例中，复合植物胶体选自由阿拉伯胶(Arabic gum)、瓜儿胶(Guar gum)、黄原胶(Xanthan)以及它们的任意组合组成的组。
在本发明的一个实施例中，复合植物胶体的含量范围介于6重量％至10重量％之间，及鱼油的含量范围介于3重量％至15重量％之间。较佳地，阿拉伯胶的含量为5.6重量％至8.4重量％；黄原胶的含量为0.16重量％至0.24重量％；瓜儿胶的含量为0.064重量％至0.096重量％；鱼油的含量为7.2重量％至10.8重量％。
在本发明的一个实施例中，微米鱼油组合物的平均粒径介于180nm至250nm。
在本发明的一个实施例中，乳化处理的持续时间介于25至45分钟之间。较佳地，乳化处理的持续时间为35分钟。
在本发明的一个实施例中，乳化处理是在15℃至30℃下进行。较佳地，乳化处理是在25℃下进行。
在本发明的一个实施例中，均质处理是在15℃至40℃下进行。较佳地，均质处理是在25℃至30℃下进行。
综上所述，本发明的微米鱼油组合物的功效在于：与市售的其它品牌乳化鱼油相比，具有良好乳化安定性，不易产生油水分离的现象；可增进个体的生物吸收性及生物可利用性；及平均粒径低于已知的鱼油产品的平均粒径，进而提高个体对于EPA及DHA的吸收率及利用率。
附图说明
图1是本发明微米鱼油组合物(即实验组)的色谱分析图。
图2是购自于美乐家有限公司的鱼油产品(即比较组)的色谱分析图。
图3是本发明微米鱼油组合物经乳化处理的外观照片。
图4是购自于美乐家有限公司的鱼油产品经乳化处理的外观照片。
图5显示本发明的微米鱼油组合物(即实验组)及购自于美乐家有限公司的鱼油产品(即比较组)经乳化处理的TSI测定结果。
图6显示本发明微米鱼油组合物经均质处理后(即实验组)的粒径分析结果。
图7显示鱼油组合物未经均质处理(即对照组)的粒径分析结果。
图8显示本发明微米鱼油组合物经均质处理后(即实验组)的粒径分布结果。
图9显示鱼油组合物未经均质处理(即对照组)的粒径分布结果。
图10显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的血浆内EPA的浓度变化，其中“#”表示p＜0.1，并且“*”表示p＜0.05。
图11显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的血浆内DHA的浓度变化，其中“#”表示p＜0.1，并且“*”表示p＜0.05。
图12显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的红血球内EPA的浓度变化，其中“#”表示p＜0.1，并且“*”表示p＜0.05。
图13显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的红血球内DHA的浓度变化，其中“#”表示p＜0.1，并且“*”表示p＜0.05。
图14显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的血浆内EPA及DHA的浓度变化，其中“#”表示p＜0.1。
图15显示受试者在服用本发明经高压(300bar至350bar)均质处理的 微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的红血球内EPA及DHA的浓度变化，其中“#”表示p＜0.1。
具体实施方式
以下将进一步说明本发明的实施方式，下述所列举的实施例是用于阐明本发明，而非用以限定本发明的范围，对于本领域普通技术人员来说，在不脱离本发明的精神和范围内，应当可做若干改进与润饰，因此本发明的保护范围应当以权利要求书所界定的范围为准。
定义
本文中所使用数值为近似值，所有实验数据皆表示在20％的范围内，较佳为在10％的范围内，最佳为在5％的范围内。
根据本发明的食品产品可制备成分散性粉末(dispersible powder)或细颗粒(granule)、溶液、悬浮液(suspension)、乳剂(emulsion)以及类似物。
根据本发明，食品产品的种类包括但不限于：健康食品(health foods)以及营养补充品(nutritional supplements)。
如本文中所使用的，用语“生物吸收性(bioabsorbability)”意指被生物体摄入并消化吸收及分解的能力。
如本文中所使用的，用语“生物可利用性(bioavailability)”意指食品产品中的活性成分(active ingredient)或活性部分(active moiety)被吸收并成为可全身性利用的速率及量。
实施例1.微米鱼油组合物的制备
首先，准备6重量％至10重量％的复合植物胶体(包括阿拉伯胶、黄原胶及瓜儿胶，其中阿拉伯胶的含量为7重量％，黄原胶的含量为0.2重量％，瓜儿胶的含量为0.08重量％，以沸水进行煮沸，然后以3,000rpm进行混合搅拌2小时，从而得到复合植物胶体母液。待复合植物胶体母液冷却至室温(25℃)，加入10重量％至15重量％的甘油及3重量％至15重量％的鱼油(较佳含量为9重量％)，接而以3,000rpm进行混合搅拌来乳化处理25分钟至45分钟，以得到乳化物。之后，将乳化物在300bar至350bar的压力下进行均质处理，以得到本发明的微米鱼油组合物。
实施例2.微米鱼油组合物的分层与稳定性分析
本实验是委托台湾的食品工业发展研究所来进行。其中，本发明的微米鱼油组合物被使用作为实验组，而购自于美乐家有限公司的鱼油产品被使用作为比较组。
2.1色谱分析
首先，利用Turbiscan分散稳定性分析仪，以55℃和4小时的条件进行色谱分析。色谱分析的数值会与乳化样品透光程度成正比。本实验的结果是显示于图1至图4。图1是本发明微米鱼油组合物(即实验组)的色谱分析图；图2是购自于美乐家有限公司的鱼油产品(即比较组)的色谱分析图；图3是本发明微米鱼油组合物经乳化处理的外观照片；以及图4是购自于美乐家有限公司的鱼油产品经乳化处理的外观照片。由图1及图2可见，与比较组相较之下，实验组的色谱分布较为集中，对照组的色谱分布较为剧烈。由图3及图4可见，与比较组相较之下，实验组经乳化处理后分层不明显，比较组经乳化处理后有明显分层。这个实验结果显示，本发明的微米鱼油组合物的乳化状况相当稳定。
2.2Turbiscan分散稳定性指标(Turbiscan stability index，TSI)测定
同样地，利用Turbiscan分散稳定性分析仪，以55℃和4小时的条件进行分析，并统合出TSI数值(稳定动力学参数)。TSI数值可反映乳化样品的稳定性，当TSI数值越高代表稳定性变动越高，也表示乳化样品分散度越不稳定。图5显示本发明的微米鱼油组合物(即实验组)及购自于美乐家有限公司的鱼油产品(即比较组)经乳化处理的TSI测定结果。由图5可见，比较组在55℃和4小时的测试过程中，TSI数值不断上升，这表示比较组的分散稳定性差；相反地，实验组的曲线在2小时后趋于平稳，这表示实验组在测试过程中变化程度较小。这个实验结果显示，本发明的微米鱼油组合物具有较佳的分散稳定性。因此，经由色谱分析与TSI(分散稳定性指标)分析，本发明微米乳化鱼油组合物与比较组(市售它牌乳化鱼油)相比，具有良好乳化安定性，不易产生油水分离的现象。
实施例3.微米鱼油组合物的粒径分析
利用高压均质机(GEA Niro Soavi)并在300bar至350bar的压力下对微 米鱼油组合物进行均质处理，以此作为实验组。未进行均质处理的鱼油组合物被使用作为对照组。接着，委托台湾大昌华嘉股份有限公司检测实验组及对照组的粒径，使用NanoSight NS300分析仪进行检测，NS300分析仪可对直径10nm至2000nm所有类型的纳米颗粒进行快速自动化的粒度分布及浓度分析。本实验结果显示于图6至图9。
图6显示本发明微米鱼油组合物经均质处理后(即实验组)的粒径分析结果；图7显示鱼油组合物未经均质处理(即对照组)的粒径分析结果；图8显示本发明微米鱼油组合物经均质处理后(即实验组)的粒径分布结果；以及图9显示鱼油组合物未经均质处理(即对照组)的粒径分布结果。由图6及图8可见，实验组的粒径尺寸主要集中在100nm至400nm，较佳地粒径介于180nm至250nm，平均粒径为216.5nm。相较之下，由图7及图9可见，对照组的粒径尺寸主要集中在100nm至700nm，平均粒径为382.8nm。这个实验结果显示，高压均质处理为本发明微米乳化鱼油降低平均粒径的关键，微米乳化鱼油的平均粒径可由382.8nm降低至216.5nm，明显降低鱼油粒径。因此，本发明的微米鱼油组合物具有较佳的生物吸收性及生物可利用性。
实施例4.微米鱼油组合物的人体吸收率及利用率分析
本实验采取交叉试验(crossover study)及安慰剂控制试验(placebo-controlled study)的形式。共募集4位健康受试者，分别摄取4.2g的本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)及未经高压均质处理的鱼油组合物(即对照组)。接着，检测服用鱼油组合物前(空腹)及服用鱼油组合物24小时后，各受试者血浆及红血球内EPA及/或DHA的浓度变化，由此评估实验组及对照组鱼油组合物的生物吸收率及利用率。试验期间皆给予受试者低脂饮食，并且避免食用鱼类、亚麻籽、螺旋藻、黑醋栗油及坚果类等会造成实验误差的食物。本实验结果显示于图10至图15。
图10显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的血浆内EPA的浓度变化；图11显示受试者在服用本发明经高压(300bar 至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的血浆内DHA的浓度变化；图12显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的红血球内EPA的浓度变化；图13显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的红血球内DHA的浓度变化；图14显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的血浆内EPA及DHA的浓度变化，即图10及图11的各小时血浆内EPA及DHA浓度变化的总和；以及图15显示受试者在服用本发明经高压(300bar至350bar)均质处理的微米鱼油组合物(即实验组)或未经高压均质处理的鱼油组合物(即对照组)后的红血球内EPA及DHA的浓度变化，即图12及图13的各小时红血球内EPA及DHA浓度变化的总和。
由图10可见，在服用鱼油组合物后的24小时内，实验组测得的血浆内EPA浓度是高于对照组；由图11可见，在服用鱼油组合物后的24小时内，实验组测得的血浆内DHA浓度是高于对照组；由图12可见，在服用鱼油组合物后的24小时内，实验组测得的红血球内EPA浓度是高于对照组；由图13可见，在服用鱼油组合物后的24小时内，除了第4小时之外，实验组测得的红血球内DHA浓度是高于对照组；由图14可见，在服用鱼油组合物后的24小时内，实验组测得的血浆内EPA及DHA浓度是高于对照组，特别在第6小时之时，实验组测得的血浆内EPA及DHA浓度是对照组的5.5倍；由图15可见，在服用鱼油组合物后的24小时内，实验组测得的红血球内EPA及DHA浓度是高于对照组，特别在第8小时之时，实验组测得的红血球内EPA及DHA浓度是对照组的7.4倍。本实施例的实验结果显示，本发明的微米鱼油组合物能够有效增进个体(例如人体)的生物吸收性及生物可利用性。
因此，前述实验结果显示，摄取经高压均质后的本发明微米鱼油组合物不论血浆或是红血球中的EPA及DHA浓度，在24小时内皆高于高压均质前的鱼油组合物。经比较后，也可发现经过高压均质后的微米鱼油组合物可提 高血浆中EPA及DHA含量5.5倍，以及提高红血球EPA及DHA含量7.4倍，可证实本发明微米乳化鱼油组合物可明显提高人体对于鱼油的吸收率及利用率。
综上所述，本发明的微米鱼油组合物经由实验证实至少具有以下功效：乳化状况稳定、优异的分散稳定性、较小的平均粒径，及有效增进个体的生物吸收性及生物可利用性。
以上所述仅为举例性，而非为限制性。任何未脱离本发明的精神与范围，而对其进行的等效修改或变更，均应包含于权利要求书中。

Claims (15)

  1. 一种用于制备微米鱼油组合物的方法，包含下列步骤：
    将复合植物胶体与鱼油混合并进行乳化处理，以得到乳化物；以及
    将该乳化物在300bar至350bar的压力下进行均质处理，以得到该微米鱼油组合物。
  2. 如权利要求1所述的方法，其中该复合植物胶体选自由阿拉伯胶、瓜儿胶、黄原胶以及它们的任意组合组成的组。
  3. 如权利要求1所述的方法，其中该复合植物胶体的含量范围介于6重量％至10重量％之间，并且该鱼油的含量范围介于3重量％至15重量％之间。
  4. 如权利要求1所述的方法，其中该微米鱼油组合物的平均粒径介于180至250nm之间。
  5. 如权利要求1所述的方法，其中该乳化处理的持续时间介于25分钟至45分钟之间。
  6. 如权利要求1所述的方法，其中该乳化处理是在15℃至30℃下进行。
  7. 如权利要求1所述的方法，其中该均质处理是在15℃至40℃下进行。
  8. 一种微米鱼油组合物，通过包含下列步骤的方法而被制得：
    将复合植物胶体与鱼油混合并进行乳化处理，以得到乳化物；以及
    将该乳化物在300bar至350bar的压力下进行均质处理，以得到该微米鱼油组合物。
  9. 如权利要求8所述的微米鱼油组合物，其中该复合植物胶体选自由阿拉伯胶、瓜儿胶、黄原胶以及它们的任意组合组成的组。
  10. 如权利要求8所述的微米鱼油组合物，其中该复合植物胶体的含量范围介于6重量％至10重量％之间，并且该鱼油的含量范围介于3重量％至15重量％之间。
  11. 如权利要求8所述的微米鱼油组合物，其中该微米鱼油组合物的平均粒径介于180nm至250nm之间。
  12. 如权利要求8所述的微米鱼油组合物，其中该乳化处理的持续时间介于25分钟至45分钟之间。
  13. 如权利要求8所述的微米鱼油组合物，其中该乳化处理是在15℃至30℃下进行。
  14. 如权利要求8所述的微米鱼油组合物，其中该均质处理是在15℃至40℃下进行。
  15. 一种如权利要求8至14中任一项所述的微米鱼油组合物在制备增进个体的生物吸收性及生物可利用性的食品产品中的用途。
PCT/CN2018/088044 2017-05-23 2018-05-23 微米鱼油组合物及其制备方法与用途 WO2018214914A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880026492.8A CN110536607A (zh) 2017-05-23 2018-05-23 微米鱼油组合物及其制备方法与用途
US16/611,663 US20200147147A1 (en) 2017-05-23 2018-05-23 Micron fish oil composition, and preparation process and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762510214P 2017-05-23 2017-05-23
US62/510,214 2017-05-23

Publications (1)

Publication Number Publication Date
WO2018214914A1 true WO2018214914A1 (zh) 2018-11-29

Family

ID=64396223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/088044 WO2018214914A1 (zh) 2017-05-23 2018-05-23 微米鱼油组合物及其制备方法与用途

Country Status (4)

Country Link
US (1) US20200147147A1 (zh)
CN (1) CN110536607A (zh)
TW (1) TWI673012B (zh)
WO (1) WO2018214914A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110742862A (zh) * 2019-11-14 2020-02-04 厦门昶科生物工程有限公司 一种虾青素乳化液及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387863A (zh) * 2002-06-07 2003-01-01 汕头市雅园生物工程有限公司 耐热型微胶囊鱼油dha营养粉制备工艺及用途
CN1768602A (zh) * 2004-11-02 2006-05-10 国家海洋药物工程技术研究中心 超临界精制甲鱼油多膜微胶囊及其制备方法
CN105326044A (zh) * 2015-11-22 2016-02-17 威海百合生物技术股份有限公司 一种复合鱼油微胶囊及其制备方法
WO2017063101A1 (zh) * 2015-10-12 2017-04-20 浙江医药股份有限公司新昌制药厂 含较多双键脂溶性营养素高稳定性微胶囊干粉/微粒的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101669920A (zh) * 2008-09-10 2010-03-17 阜宁怀仁生物有限公司 一种强抗氧化型dha微囊及其制备方法
CN101966202A (zh) * 2010-10-27 2011-02-09 南通迈特生物工程有限公司 一种无鱼腥味的多维鱼油乳组合物及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387863A (zh) * 2002-06-07 2003-01-01 汕头市雅园生物工程有限公司 耐热型微胶囊鱼油dha营养粉制备工艺及用途
CN1768602A (zh) * 2004-11-02 2006-05-10 国家海洋药物工程技术研究中心 超临界精制甲鱼油多膜微胶囊及其制备方法
WO2017063101A1 (zh) * 2015-10-12 2017-04-20 浙江医药股份有限公司新昌制药厂 含较多双键脂溶性营养素高稳定性微胶囊干粉/微粒的制备方法
CN105326044A (zh) * 2015-11-22 2016-02-17 威海百合生物技术股份有限公司 一种复合鱼油微胶囊及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI LUFENG: "Microencapsulation of fish oil", CHINA OILS AND FATS, vol. 37, no. 10, 31 December 2012 (2012-12-31), pages 22 - 24 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110742862A (zh) * 2019-11-14 2020-02-04 厦门昶科生物工程有限公司 一种虾青素乳化液及其制备方法

Also Published As

Publication number Publication date
TWI673012B (zh) 2019-10-01
US20200147147A1 (en) 2020-05-14
CN110536607A (zh) 2019-12-03
TW201900039A (zh) 2019-01-01

Similar Documents

Publication Publication Date Title
McClements Development of next-generation nutritionally fortified plant-based milk substitutes: Structural design principles
Lavanya et al. Influence of spray-drying conditions on microencapsulation of fish oil and chia oil
CN105053276B (zh) 无蔗糖功能性牡丹籽油粉末油脂的制备方法
Wang et al. Development and evaluation of microencapsulated peony seed oil prepared by spray drying: Oxidative stability and its release behavior during in-vitro digestion
Gallardo et al. Microencapsulation of linseed oil by spray drying for functional food application
CN102036661B (zh) 维生素衍生物及其用途
CN102131407B (zh) 含有非极性化合物的组合物
CN105104584B (zh) 含活性肽的牡丹籽油粉末油脂的制备方法
CN110301483A (zh) 富勒烯类化合物的用途以及富勒烯微囊粉及其制备方法和应用
Ivanov et al. Flaxseed additive application in dairy products production
CN107080734A (zh) 包含生育酚的peg衍生物的乳剂
Santhanam et al. Delivery of omega-3 fatty acids into cake through emulsification of fish oil-in-milk and encapsulation by spray drying with added polymers
CN107660620A (zh) 一种羊基油脂微胶囊粉末及其制备方法
Malinauskytė et al. Impact of interfacial composition on emulsion digestion using in vitro and in vivo models
Almasi et al. Yogurt fortified with omega‐3 using nanoemulsion containing flaxseed oil: Investigation of physicochemical properties
Nagachinta et al. Spray‐dried structured lipid containing long‐chain polyunsaturated fatty acids for use in infant formulas
Khan et al. Bioavailability, rheology, and sensory evaluation of mayonnaise fortified with vitamin D encapsulated in protein‐based carriers
Lin et al. Influence of different solid lipids on the properties of a novel nanostructured lipid carrier containing Antarctic krill oil
Homroy et al. Role of encapsulation on the bioavailability of omega‐3 fatty acids
WO2018214914A1 (zh) 微米鱼油组合物及其制备方法与用途
CN107846953A (zh) 呈容易混合形式的具有改善的亲脂性溶解度和生物利用度的营养产品
Vieira et al. The benefits of omega-3 fatty acid nanocapsulation for the enrichment of food products: a review
Mohideen et al. Effects of blueberry (Vaccinium corymbosum) juice on lipid oxidation during spray drying of microencapsulated menhaden Oil
TWI667022B (zh) 無魚腥臭味之魚油組合物及其製備方法
Dizaj et al. Nanoemulsion-based delivery systems: preparation and application in the food industry

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18805295

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18805295

Country of ref document: EP

Kind code of ref document: A1